Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2007-12-21 Annual Report
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
ANNUAL REPORT OF SMALL BUSINESS FOR PERIOD ENDED SEPTEMBER 30, 2007
Annual Report Classification · 100% confidence The document is titled 'Form 10-KSB' and is described as an 'Annual Report of Small Business' for the fiscal year ended September 30, 2007. It is filed with the United States Securities and Exchange Commission (SEC) and contains detailed sections typical of an annual report, including business description, management discussion and analysis, financial statements, legal proceedings, executive compensation, and other comprehensive disclosures. The length of the document (15,000 characters) and the presence of substantive financial and operational information confirm it is the full annual report filing rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2007-12-21 English
MAIN DOCUMENT DESCRIPTION
Director's Dealing
2007-12-11 English
CURRENT REPORT, DATED OCTOBER 22, 2007
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 22, 2007. It reports the entry into a material definitive agreement, specifically an amendment to the employment agreement of a senior executive (David W. Morgan). The document includes the amendment details and the signature of a company officer. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The primary content is an announcement of a management contract amendment, which fits best under Board/Management Information (MANG) as it relates to changes in senior management agreements. The document length is 3221 characters, which is short and consistent with a regulatory announcement rather than a full report.
2007-10-23 English
CURRENT REPORT DATED OCTOBER 16, 2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated October 16, 2007. It includes a Regulation FD Disclosure about investor presentation materials attached as Exhibit 99.1 and posted on the company's website. The document does not contain actual financial statements or detailed financial analysis but rather announces the availability of presentation materials for investors. The length is 4382 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like an investor presentation (IP) since the presentation is only referenced as an exhibit and not included in full here.
2007-10-16 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a letter from a company to the SEC responding to comments on a previously filed Form 8-K. It discusses audit firm engagement and changes, references Form 8-K filings, and includes a request for an updated Exhibit 16 letter from former accountants. The content is primarily correspondence related to regulatory compliance and audit firm changes, not the audit report itself or a full financial report. The document length is about 5,190 characters, and it is a response letter rather than a standalone report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory correspondence and compliance documents that do not fit other categories.
2007-09-17 English
AMENDMENT NO. 1 TO CURRENT REPORT DATED 8/30/2007
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a Current Report filed with the SEC. It discusses changes in the company's certifying accountant, referencing prior filings and audit reports but does not itself contain financial statements or detailed audit results. It includes a letter from the prior auditor confirming agreement with disclosed statements. The document is primarily an update and disclosure about auditor changes rather than the audit report itself or a full financial report. Given the nature of the content and the regulatory context, this filing fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2007-09-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.